bis(diisopropylamido)phosphoric acid 2-cyanoethyl ester | 128312-25-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: bis(diisopropylamido)phosphoric acid 2-cyanoethyl ester
• 英文别名: 2-cyanoethyl tetraisopropylphosphorodiamidite；2-cyanoethyl-N,N,N,N-tetraisopropylphosphorodiamidite；2-cyanoethyl tetrakis(1-methylethyl)phosphorodiamidoate；(2-cyanoethoxy)-tetraisopropylphosphordiamidite；2-cyanoethyl N,N,N′,N′-tetraisopropyl-phosphoro-diamidite；2-cyanoethyl N,N,N′,N′-tetraisopropylphosphordiamidite；2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphorodiamide；2-cyanoethyl-N,N,N',N'-tetraisopropylphosphordiamidite；Phosphorodiamidic acid, tetrakis(1-methylethyl)-, 2-cyanoethyl ester；3-bis[di(propan-2-yl)amino]phosphoryloxypropanenitrile
• CAS: 128312-25-4
• 化学式: C₁₅H₃₂N₃O₂P
• 分子量: 317.412
• InChiKey: JSSFYPGPWGGXNJ-UHFFFAOYSA-N

物化性质

• 沸点：
  396.1±44.0 °C(Predicted)
• 密度：
  1.004±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  56.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-di-O-acetyluridine 、 bis(diisopropylamido)phosphoric acid 2-cyanoethyl ester 在 二异丙基铵盐四氮唑 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以95%的产率得到2',3'-di-O-acetyluridine-5'-O-yl(2-cyanoethoxy)(diisopropylamino)phosphane
  参考文献：
  名称：

  作为 UDP-GlcNAc 2-差向异构酶抑制剂的 C-糖苷 UDP-GlcNAc 类似物

  摘要：

  神经氨酸生物合成的第一步，即 UDP-GlcNAc 到 ManNAc 的“差向异构化”，是由 UDP-GlcNAc 2-差向异构酶催化的。在本文中，我们报告了 C-糖苷 UDP-GlcNAc 类似物 1-5 的合成，作为该酶的基于底物的抑制剂。重点是糖和 UDP 部分之间连接的最佳距离和几何形状，这对于 UDP-GlcNAc 2-差向异构酶的识别都很重要。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004)

  DOI：

  10.1002/ejoc.200400197

文献信息

• SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI
  申请人：DELIVERSIR LTD.

  公开号：US20160039850A1

  公开（公告）日：2016-02-11

  The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.

  本发明涉及一种新型递送系统，用于将治疗剂递送到活细胞中，更具体地说，涉及设计用于靶向和/或穿透细胞或其他感兴趣目标的新型化学基团，进一步能够将治疗剂结合到这些细胞中以进行递送，并涉及含有相同化学基团的递送系统。
• Synthesis and Characterization of Oligodeoxynucleotides Containing an N1 β-Hydroxyalkyl Adduct of 2‘-Deoxyinosine
  作者：Agnieszka Kowalczyk、Constance M. Harris、Thomas M. Harris

  DOI：10.1021/tx010025r

  日期：2001.6.1

  has been developed for synthesis of oligonucleotides containing N1-adducted 2'-deoxyinosines. The 2'-deoxyinosine adduct of 3,4-epoxy-1-butene was prepared from (+/-)-4-acetoxy-3-bromo-1-butene and tetraisopropyldisiloxanediyl-protected 2'-deoxyinosine with base. The 2'-deoxyinosine derivative was then incorporated into the oligodeoxynucleotide sequence 5'-d(CGGACXAGAAG)-3' (X = N1-(1-hydroxy-3-bu

  由简单的环氧化物在腺嘌呤核苷的N1位反应产生的羟乙基加合物可以脱氨基生成肌苷类似物，如果在DNA中形成，则被怀疑具有高度致突变性。已经开发出一种用于合成包含N1加成的2'-脱氧肌苷的寡核苷酸的方法。3，4-环氧-1-丁烯的2'-脱氧肌苷加合物由（+/-）-4-乙酰氧基-3-溴-1-丁烯和四异丙基二硅氧烷二基保护的2'-脱氧肌苷与碱制备。然后将2′-脱氧肌苷衍生物掺入寡脱氧核苷酸序列5′-d（CGGACXAGAAG）-3′（X ＝ N1-（1-羟基-3-丁烯-2-基）-2′-脱氧肌苷）。
• Antisense modulation of MARK3 expression
  申请人：Isis Pharmaceuticals Inc.

  公开号：US20030232771A1

  公开（公告）日：2003-12-18

  Antisense compounds, compositions and methods are provided for modulating the expression of MARK3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MARK3. Methods of using these compounds for modulation of MARK3 expression and for treatment of diseases associated with expression of MARK3 are provided.

  提供了用于调节MARK3表达的反义化合物、组合物和方法。这些组合物包括针对编码MARK3的核酸的反义化合物，特别是反义寡核苷酸。提供了使用这些化合物调节MARK3表达和治疗与MARK3表达相关疾病的方法。
• [EN] NOVEL CHELATING AGENTS AND CHELATES AND THEIR USE<br/>[FR] NOUVEAUX AGENTS CHELATEURS, NOUVEAUX CHELATES ET LEUR UTILISATION
  申请人：WALLAC OY

  公开号：WO2005021538A1

  公开（公告）日：2005-03-10

  This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.

  这项发明涉及一组新型螯合剂、新型螯合物、用所述螯合物或螯合剂标记的生物分子，以及与所述螯合物、螯合剂或标记的生物分子结合的固相支持物。特别是该发明涉及在寡核苷酸或寡肽的固相合成中有用的新型螯合剂，以及由此获得的寡核苷酸和寡肽。
• Chloroquine combination drugs and methods for their synthesis
  申请人：Kosak M. Kenneth

  公开号：US20070060499A1

  公开（公告）日：2007-03-15

  This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

  这项发明揭示了氯喹偶联活性药剂的组合物，包括其制备方法。先前的技术已经表明，以足够高浓度给予氯喹作为游离药物，可以增强细胞内体内各种药剂从细胞内体释放到细胞质中。这些组合物的目的是在传递活性药剂的相同部位提供受控量的氯喹，从而减少所需的总剂量。这些组合物包括将氯喹物质直接或通过各种药用载体物质偶联到活性药剂。载体物质包括多糖、合成聚合物、蛋白质、胶束和其他用于在体内携带和释放氯喹组合物以产生治疗效果的物质。这些组合物还可以包括用于携带和释放活性药剂以用于治疗或其他医疗用途的生物可降解连接。该发明还揭示了与靶向分子偶联的载体组合物，用于将氯喹物质和活性药剂定位传递到它们的作用部位。